Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O/AZD2281) in combination with carboplatin (C) in ovarian cancer (OvCa) patients with BRCA1/2 mutations (OvCaMUT +) and high grade serous OvCa (HGSOC) with low genetic risk (NCT00647062)

Objective: Olaparib (O) is a PARPi with single-agent activity against OvCa in BRCA1/2MUT + carriers. Approximately 50% of HGSOC are deficient in homologous recombination due to germline BRCA1/2MUT + or acquired deficits in DNA double-strand break repair. We hypothesized that the addition of C to O to stress the DNA repair machinery would improve the clinical benefit of C in OvCaMUT + and HGSOC.